Skip to Content

Two New Compounds Have Been Discovered and May Treat Both Alcohol and Cigarette Addictions


A report published in the issue of Neuropsychopharmacology on November 3, 2010 describes a clinical trial led by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco and Pfizer Inc. pharmaceutical company.

Lab Clinical Study

During the study researchers discovered that when they gave rodents alcohol the consumption was severely decreased. This is how they found the two genes alpha 3 and Beta 4. These two genes target the neuronal nicotinic acetylcholine receptor.

Human Clinical Studies

Recent studies have proven that genes that are encoded with the alpha 3 and Beta 4 compounds are extremely important in an individuals susceptibility to both nicotine and alcohol dependency.

The Compounds

The two compounds that researchers believe will help with alcohol and nicotine dependency are CP-601932 and PF-4575180 both of which were developed by Pfizer Inc.

The compound CP-601932 has already proven to be safe for humans. The misconception is that alcohol and nicotine need to be treated as two separate disorders/diseases. When in fact the nAChRs (proteins found in the brain and central nervous system that mediate the effects of substances such as nicotine and alcohol can quite possible be treated by the use of one compound.


The compound had a significant effect on the rodents’ alcohol consumption, their intake of sucrose (glucose) was not affected. “This indicates that unlike currently approved alcohol abuse medications, the compounds do not interfere with the brains natural reward system in a larger way,” says Selena E. Bartlett, PhD.

Dr. Bartlett states “our data suggests that by targeting specific nAChR subtypes, it may be possible to treat both alcohol and nicotine dependence with one medication.”